Cryopreserved placental tissue allograft accelerates time to continence following robot-assisted radical prostatectomy

J Robot Surg. 2021 Dec;15(6):877-883. doi: 10.1007/s11701-020-01187-z. Epub 2021 Jan 11.

Abstract

Intra-operatively placed cryopreserved placental tissue allograft (CPTA) has shown promise in expediting the recovery urinary continence (UC) following robot-assisted radical prostatectomy (RARP). In this retrospective review of a prospectively maintained single-surgeon, single-institution RARP database, we compare three groups of patients: historical controls (C; N = 183 men) that received no allograft versus two different CPTA products (total CPTA N = 162 [A1 N = 81; A2 N = 81]). The CPTA product was intra-operatively placed as an onlay over the area of the neurovascular bundles during RARP. CPTA cases had significantly faster median time to UC (A1 = 1.4 months; A2 = 1.45 months) versus controls (1.64 months), p = 0.01. On multivariable analysis, use of A1 (HR 1.55, 95% CI [1.14-2.09], p = 0.005) and use of A2 (HR 1.53, CI [1.11-2.11], p = 0.01) were significantly associated with quicker return of UC. Older age (HR 0.97, CI [0.96-0.99], p = 0.001) and non-organ-confined clinical stage (HR 0.51, CI [0.26-1.0] p = 0.05), were significantly associated with slower return of UC. In a propensity score-matched analysis of 77 CPTA patients with sufficient follow-up versus controls, there was significantly less biochemical recurrence (BCR; p = 0.01). Our study indicates that CPTA use appears to accelerate time to UC in age- and performance status-matched men undergoing RARP without increased risk of BCR.

Keywords: Biochemical recurrence; Cryopreserved placental tissue allograft; Incontinence; Prostate cancer.

MeSH terms

  • Aged
  • Allografts
  • Humans
  • Male
  • Placenta
  • Pregnancy
  • Prostatectomy / adverse effects
  • Prostatic Neoplasms* / surgery
  • Recovery of Function
  • Retrospective Studies
  • Robotic Surgical Procedures* / methods
  • Robotics*
  • Treatment Outcome